{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:03:42Z","timestamp":1774436622451,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To identify reasons for negative histopathology of specimens from prostate-specific membrane antigen (PSMA) radioguided surgery (PSMA-RGS) in recurrent prostate cancer (PCa) after prostatectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Of 302 patients who underwent PSMA-RGS, 17 (5.6%) demonstrated a negative histopathology. Preoperative data, PSMA PET, PSMA SPECT, and follow-up information were analyzed retrospectively to differentiate true\/false positive (TP\/FP) from true\/false negative (TN\/FN) lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median prostate-specific antigen at PET was 0.4 ng\/ml (interquartile range [IQR] 0.3\u20131.2). Twenty-five index lesions (median short axis 7 mm, IQR 5\u20138; median long-axis 12 mm, IQR 8\u201317) had a median SUVmax of 4 (IQR 2.6\u20136; median PSMA expression score 1, IQR 1\u20131). Six lesions were TP, twelve were FP, one was TN, and six remained unclear. All TP lesions were in the prostatic fossa or adjacent to the internal iliac arteries. Three suspected local recurrences were FP. All FP lymph nodes were located at the distal external iliac arteries or outside the pelvis. A low PSMA-expressing TN node was identified next to a common iliac artery. Unclear lesions were located next to the external iliac arteries or outside the pelvis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In most cases with a negative histopathology from PSMA-RGS, lesions were FP on PSMA PET. Unspecific uptake should be considered in low PSMA-expressing lymph nodes at the distal external iliac arteries or outside the pelvis, especially if no PSMA-positive lymph nodes closer to the prostatic fossa are evident. Rarely, true positive metastases were missed by surgery or histopathology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06442-7","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:04:04Z","timestamp":1695715444000},"page":"548-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-9627","authenticated-orcid":false,"given":"Daniel","family":"Koehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Shenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivayla","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Klutmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bud\u00e4us","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Knipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"6442_CR1","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. Arnhem, The Netherlands. 2023. https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed 16 May 2023."},{"key":"6442_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910\u20134. https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb.","journal-title":"J Urol."},{"key":"6442_CR3","doi-asserted-by":"publisher","unstructured":"Freedland SJ, Humphreys EB, Mangold L, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer \u2013 specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294:433\u20139. https:\/\/doi.org\/10.1001\/jama.294.4.433.","DOI":"10.1001\/jama.294.4.433"},{"key":"6442_CR4","doi-asserted-by":"publisher","unstructured":"Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67:1009\u201316. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.028.","DOI":"10.1016\/j.eururo.2014.09.028"},{"key":"6442_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/pros.23511","volume":"78","author":"RS Pompe","year":"2018","unstructured":"Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, et al. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate. 2018;78:676\u201381. https:\/\/doi.org\/10.1002\/pros.23511.","journal-title":"Prostate."},{"key":"6442_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","volume":"82","author":"TM Ma","year":"2022","unstructured":"Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, et al. Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN). Eur Urol. 2022;82:487\u201398. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.011.","journal-title":"Eur Urol."},{"key":"6442_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75:967\u201387. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.011.","journal-title":"Eur Urol."},{"key":"6442_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.117.202945","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, et al. Impact of 68 Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59:434\u201341. https:\/\/doi.org\/10.2967\/jnumed.117.202945.","journal-title":"J Nucl Med."},{"key":"6442_CR9","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61:1793\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.242180.","journal-title":"J Nucl Med."},{"key":"6442_CR10","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1007\/s00259-020-04809-8","volume":"47","author":"D Deandreis","year":"2020","unstructured":"Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, et al. 68Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2020;47:2804\u201315. https:\/\/doi.org\/10.1007\/s00259-020-04809-8.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6442_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/JNUMED.120.261886","volume":"63","author":"JJ Cerci","year":"2022","unstructured":"Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET\/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med. 2022;63:240\u20137. https:\/\/doi.org\/10.2967\/JNUMED.120.261886.","journal-title":"J Nucl Med."},{"key":"6442_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11050710","volume":"11","author":"G Treglia","year":"2019","unstructured":"Treglia G, Annunziata S, Pizzuto DA, Giovanella L, Prior JO, Ceriani L. Detection rate of18 F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel). 2019;11:1\u201314. https:\/\/doi.org\/10.3390\/cancers11050710.","journal-title":"Cancers (Basel)."},{"key":"6442_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol."},{"key":"6442_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.929444","volume":"12","author":"M Alberto","year":"2022","unstructured":"Alberto M, Yim A, Papa N, Siva S, Ischia J, Touijer K, et al. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol. 2022;12:1\u201310. https:\/\/doi.org\/10.3389\/fonc.2022.929444.","journal-title":"Front Oncol."},{"key":"6442_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","volume":"1","author":"A Kneebone","year":"2018","unstructured":"Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. Eur Assoc Urol. 2018;1:531\u20137. https:\/\/doi.org\/10.1016\/j.euo.2018.04.017.","journal-title":"Eur Assoc Urol."},{"key":"6442_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol."},{"key":"6442_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","volume":"5","author":"T H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher T, Baumann M, Kotzerke J, Z\u00f6phel K, Paulsen F, M\u00fcller AC, et al. Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial. Eur Urol Oncol. 2022;5:44\u201351. https:\/\/doi.org\/10.1016\/j.euo.2021.10.002.","journal-title":"Eur Urol Oncol."},{"key":"6442_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bju.13713","volume":"120","author":"I Rauscher","year":"2017","unstructured":"Rauscher I, D\u00fcwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, et al. Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int. 2017;120:40\u20137. https:\/\/doi.org\/10.1111\/bju.13713.","journal-title":"BJU Int."},{"key":"6442_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2967\/jnumed.116.178939","volume":"58","author":"S Robu","year":"2017","unstructured":"Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235\u201342. https:\/\/doi.org\/10.2967\/jnumed.116.178939.","journal-title":"J Nucl Med."},{"key":"6442_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.eururo.2019.03.045","volume":"76","author":"T Horn","year":"2019","unstructured":"Horn T, Kr\u00f6nke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in rec. Eur Urol. 2019;76:517\u201323. https:\/\/doi.org\/10.1016\/j.eururo.2019.03.045.","journal-title":"Eur Urol."},{"key":"6442_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","volume":"75","author":"T Maurer","year":"2019","unstructured":"Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99m Technetium-based prostate-specific membrane antigen\u2013radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75:659\u201366. https:\/\/doi.org\/10.1016\/j.eururo.2018.03.013.","journal-title":"Eur Urol."},{"key":"6442_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","volume":"67","author":"N Suardi","year":"2015","unstructured":"Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299\u2013309. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.011.","journal-title":"Eur Urol."},{"key":"6442_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","volume":"78","author":"CA Bravi","year":"2020","unstructured":"Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol. 2020;78:661\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.043.","journal-title":"Eur Urol."},{"issue":"22","key":"6442_CR24","doi-asserted-by":"publisher","first-page":"02408","DOI":"10.1016\/j.eururo.2022.05.031","volume":"S0302\u20132838","author":"S Knipper","year":"2022","unstructured":"Knipper S, Mehdi Irai M, Rauscher I, Simon R, Eiber M, van Leeuwen FW, et al. Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery. Eur Urol. 2022;S0302\u20132838(22):02408\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.031.","journal-title":"Eur Urol."},{"key":"6442_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials ( PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol."},{"key":"6442_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b13ca2.","journal-title":"Ann Surg."},{"key":"6442_CR27","unstructured":"SankeyMATIC: a Sankey diagram builder for everyone. 2023. https:\/\/sankeymatic.com. Accessed 30 May 2023."},{"key":"6442_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.euf.2018.09.014","volume":"5","author":"S Knipper","year":"2019","unstructured":"Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, et al. Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery. Eur Urol Focus. 2019;5:50\u20133. https:\/\/doi.org\/10.1016\/j.euf.2018.09.014.","journal-title":"Eur Urol Focus."},{"key":"6442_CR29","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five Different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192\u20138.","journal-title":"Cancer Res."},{"key":"6442_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628\u201336. https:\/\/doi.org\/10.1007\/s00268-005-0544-5.","journal-title":"World J Surg."},{"key":"6442_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","volume":"62","author":"M Kroenke","year":"2021","unstructured":"Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester HJ, et al. Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity. J Nucl Med. 2021;62:1082\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.251447.","journal-title":"J Nucl Med."},{"key":"6442_CR32","doi-asserted-by":"publisher","unstructured":"Hober\u00fcck S, L\u00f6ck S, Borkowetz A, Sommer U, Winzer R, Z\u00f6phel K et al. Intraindividual comparison of [68\u00a0Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. Springer Berlin Heidelberg. 2021; 11. https:\/\/doi.org\/10.1186\/s13550-021-00845-z.","DOI":"10.1186\/s13550-021-00845-z"},{"key":"6442_CR33","doi-asserted-by":"publisher","unstructured":"Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68\u00a0Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. Springer Berlin Heidelberg. 2022; 49:763\u201376. https:\/\/doi.org\/10.1007\/s00259-021-05520-y.","DOI":"10.1007\/s00259-021-05520-y"},{"key":"6442_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2967\/jnumed.119.235374","volume":"61","author":"A Farolfi","year":"2020","unstructured":"Farolfi A, Ilhan H, Gafita A, Calais J, Barbato F, Weber M, et al. Mapping prostate cancer lesions before and after unsuccessful salvage lymph node dissection using repeat psma pet. J Nucl Med. 2020;61:1037\u201342. https:\/\/doi.org\/10.2967\/jnumed.119.235374.","journal-title":"J Nucl Med."},{"key":"6442_CR35","doi-asserted-by":"publisher","unstructured":"Koehler D, Sauer M, Klutmann S, Apostolova I, Lehnert W, Bud\u00e4us L et al. Feasibility of 99m Tc-MIP-1404 for SPECT\/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients. J Nucl Med. 2022; Society of Nuclear Medicine. jnumed.122.263892. https:\/\/doi.org\/10.2967\/jnumed.122.263892.","DOI":"10.2967\/jnumed.122.263892"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06442-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06442-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06442-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:03:09Z","timestamp":1704704589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06442-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6442"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06442-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local institutional review board (IRB) approved this retrospective single-center study and waived the requirement for informed consent (PV7316).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for PSMA-RGS was given by all patients. In accordance with \u00a712 Hamburgisches Krankenhausgesetz (Hamburg Hospital Law), no informed consent for the retrospective analysis of the anonymized data was necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}